Tamoxifen-loaded PLA/DPPE-PEG lipid-polymeric nanocapsules for inhibiting the growth of estrogen-positive human breast cancer cells through cell cycle arrest
Source abstract
Abstract
The strategy of drug encapsulation with biocompatible polymeric nanocapsules could be a promising approach to improve the delivery of poorly water-soluble drugs for cancer therapy. The aim of this study was to investigate the drug delivery of tamoxifen from biocompatible nanocapsules made of poly(D,L-lactide) (PLA) core and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DPPE-PEG) shell in the treatment of breast cancer. The analytical techniques such as FTIR, XRD, SEM, and TEM were used to investigate the structure of nanocapsules. Tamoxifen drug encapsulation efficiency and loading percentages as well as release kinetics at different pH values and temperatures were used to confirm the appropriate performance of these novel nanocapsules. The maximum tamoxifen release occurred at 40 °C, pH = 4. Based on the SEM and TEM images, the sizes of nanocapsules were between 57 and 159 nm. In order to investigate the anticancer effects and cytotoxicity of encapsulated tamoxifen in PLA/DPPE-PEG nanocapsules, the tetrazolium-based colorimetric (MTT) assay and cell cycle arrest analysis on MCF-7 breast cancer cell were performed. Also, cell cycle–related gene expressions of p53 and p21 in treated MCF-7 cells with tamoxifen-loaded PLA/DPPE-PEG nanocapsules were evaluated. The results of MTT cell proliferation experiments exhibited an increase in the cytotoxicity of tamoxifen nanocapsules on MCF-7 cell line compared with free tamoxifen. The 1.2-fold increase in the G1 stage compared with the control group in the cell cycle arrest protocol as well as the notable overexpression of p53 and p21 genes suggested that these nanocapsules arrested cell cycle in MCF-7 cells.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · biodegradable polymer synthesis and properties · Biopolymer Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (80)
Show source-provided references
1. Abbas T, Dutta A (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9(6):400–41410.1038/nrc2657 ↗
2. Ahmad I (2018) Tamoxifen a pioneering drug: an update on the therapeutic potential of tamoxifen derivatives. Eur J Med Chem 143:515–53110.1016/j.ejmech.2017.11.056 ↗
3. Akbari A, Akbarzadeh A, Rafiee Tehrani M, Cohan RA, Mozaffari A, Memarzadeh M (2020) Preparation and evaluation of a liposome drug delivery system in cancer treatment in vitro. J Nanostruct 10(1):140–147
4. Alias D, Yunus R, Chong GH, Abdullah CA (2017) Single step encapsulation process of tamoxifen in biodegradable polymer using supercritical anti-solvent (SAS) process. Powder Technol 309:89–9410.1016/j.powtec.2016.12.039 ↗
5. Beh CY, Rasedee A, Selvarajah GT, Yazan LS, Omar AR, Foong JN, How CW, Foo JB (2019) Enhanced anti-mammary gland cancer activities of tamoxifen-loaded erythropoietin-coated drug delivery system. PLoS One 14(7):e021928510.1371/journal.pone.0219285 ↗
6. Bou S, Wang X, Anton N, Bouchaala R, Klymchenko AS, Collot M (2020) Lipid-core/polymer-shell hybrid nanoparticles: synthesis and characterization by fluorescence labeling and electrophoresis. Soft Matter 16:4173–418110.1039/D0SM00077A ↗
7. Chan JM, Zhang L, Yuet KP, Liao G, Rhee JW, Langer R, Farokhzad OC (2009) PLGA–lecithin–PEG core–shell nanoparticles for controlled drug delivery. Biomaterials 30(8):1627–163410.1016/j.biomaterials.2008.12.013 ↗
8. Chen W, Glackin CA, Horwitz MA, Zink JI (2019) Nanomachines and other caps on mesoporous silica nanoparticles for drug delivery. Acc Chem Res 52(6):1531–154210.1021/acs.accounts.9b00116 ↗
9. Cheng FF, Zhang JJ, Xu F, Hu LH, Abdel-Halim ES, Zhu JJ (2013) pH-sensitive polydopamine nanocapsules for cell imaging and drug delivery based on folate receptor targeting. J Biomed Nanotechnol 9(7):1155–116310.1166/jbn.2013.1611 ↗
10. Cheraghi M, Negahdari B, Daraee H, Etemadi A (2017) Heart targeted nanoliposomal/nanoparticles drug delivery: an updated review. Biomed Pharmacother 86:316–32310.1016/j.biopha.2016.12.009 ↗
11. Chevalier MT, Rescignano N, Martin-Saldaña S, González-Gómez Á, Kenny JM, San Román J, Mijangos C, Álvarez VA (2017) Non-covalently coated biopolymeric nanoparticles for improved tamoxifen delivery. Eur Polym J 95:348–35710.1016/j.eurpolymj.2017.08.031 ↗
12. Chime SA, Akpa PA, Attama AA (2019) The utility of lipids as nanocarriers and suitable vehicle in pharmaceutical drug delivery. Current Nanomater 4(3):160–17510.2174/2405461504666191016091827 ↗
13. Darzynkiewicz Z, Huang X, Zhao H (2017) Analysis of cellular DNA content by flow cytometry. Curr Protoc Immunol 119(1):5–710.1002/cpim.36 ↗
14. Date T, Nimbalkar V, Kamat J, Mittal A, Mahato RI, Chitkara D (2018) Lipid-polymer hybrid nanocarriers for delivering cancer therapeutics. J Control Release 271:60–7310.1016/j.jconrel.2017.12.016 ↗
15. Dimer FA, Carvalho-Wodarz CS, Goes A, CirnskiK HJ, Schmitt V, Pätzolde L, Abed N, Rossi CD, Bischoff M, Couvreur P, Müller R, Lehr CM (2019) PLGA nanocapsules improve the delivery of clarithromycin to kill intracellular Staphylococcus aureus and Mycobacterium abscessus. Nanomed Nanotechnol 24:10212510.1016/j.nano.2019.102125 ↗
16. Du L, Jin Y, Zhou W, Zhao J (2011) Ultrasound-triggered drug release and enhanced anticancer effect of doxorubicin-loaded poly (D, L-lactide-co-glycolide)-methoxy-poly (ethylene glycol) nanodroplets. Ultrasound Med Biol 37(8):1252–125810.1016/j.ultrasmedbio.2011.05.012 ↗
17. Elmowafy EM, Tiboni M, Soliman ME (2019) Biocompatibility, biodegradation and biomedical applications of poly (lactic acid)/poly (lactic-co-glycolic acid) micro and nanoparticles. J Pharm Investig 49:347–38010.1007/s40005-019-00439-x ↗
18. Elsabahy M, Wooley KL (2012) Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev 41(7):2545–256110.1039/c2cs15327k ↗
19. Elzoghby AO, Mostafa SK, Helmy MW, ElDemellawy MA, Sheweita SA (2017) Superiority of aromatase inhibitor and cyclooxygenase-2 inhibitor combined delivery: hyaluronate-targeted versus PEGylated protamine nanocapsules for breast cancer therapy. Int J Pharm 529(1–2):178–19210.1016/j.ijpharm.2017.06.077 ↗
20. Fedorova O, Petukhov A, Daks A (2019) Orphan receptor NR4A3 is a novel target of p53 that contributes to apoptosis. Oncogene 38:2108–212210.1038/s41388-018-0566-8 ↗
21. Fontana MC, Beckenkamp A, Buffon A, Beck RC (2014) Controlled release of raloxifene by nanoencapsulation: effect on in vitro antiproliferative activity of human breast cancer cells. Int J Nanomedicine 9:2979–2991
22. Francavilla A, Polimeno L, Dileo A, Barone M, Ove P, Coetzee M, Eagon P, Makowka L, Ambrosino G, Mazzaferro V, Starzl TE (1989) The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro. Hepatol 9(4):614–62010.1002/hep.1840090417 ↗
23. Fu S, Zhang Y, Guan S, Huang Q, Wang R, Tian R, Zang M, Qiao S, Zhang X, Liu S, Fan X (2018) Reductive-responsive, single-molecular-layer polymer nanocapsules prepared by lateral-functionalized pillar [5] arenes for targeting anticancer drug delivery. ACS Appl Mater Interfaces 10(17):14281–1428610.1021/acsami.8b03534 ↗
24. Gao W, Chan JM, Farokhzad CO (2010) pH-responsive nanoparticles for drug delivery. Mol Pharm 7(6):1913–192010.1021/mp100253e ↗
25. Gao Q, Zhu X, Chen J, Mao C, Zhang L, Xu Z (2016) Upregulation of p53 promoted G1arrest and apoptosis in human umbilical cord vein endothelial cells from preeclampsia. J Hypertens 34(7):1380–138810.1097/HJH.0000000000000944 ↗
26. Gartel AL, Tyner AL (2002) The role of the cyclin-dependent kinase inhibitor p21 in apoptosis 1 supported in part by NIH grant R01 DK56283 (to ALT) for the p21 research and campus research board and Illinois Department of Public Health Penny Severns Breast and Cervical Cancer grants (to ALG). Mol Cancer Ther 1(8):639–649
27. Gomes MLS, Nascimento NS, Borsato DM, Pretes AP, Nadal JM, Novatski A, Gomes RZ, Fernandes D, Farago PV, Zanin SMW (2019) Long-lasting anti-platelet activity of cilostazol from poly(ε-caprolactone)-poly(ethylene glycol) blend nanocapsules. Mater Sci Eng C 94:694–70210.1016/j.msec.2018.10.029 ↗
28. Han S, Dwivedi P, Mangrio FA, Dwivedi M, Khatik R, Cohn DE, Si T, Xu RX (2019) Sustained release paclitaxel-loaded core-shell-structured solid lipid microparticles for intraperitoneal chemotherapy of ovarian cancer. Artif Cells Nanomed Biotechnol 47(1):957–96710.1080/21691401.2019.1576705 ↗
29. Jain AK, Swarnakar NK, Godugu C, Singh RP, Jain S (2011) The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials 32(2):503–51510.1016/j.biomaterials.2010.09.037 ↗
30. Kathle PK, Gautam N, Kesavan K (2018) Tamoxifen citrate loaded chitosan-gellan nanocapsules for breast cancer therapy: development, characterisation and in vitro cell viability study. J Microencapsul 35(3):292–30010.1080/02652048.2018.1477844 ↗
31. Kojima T, Katoh F, Matsuda Y, Teraoka R, Kitagawa S (2008) Physicochemical properties of tamoxifen hemicitrate sesquihydrate. Int J Pharm 352:146–15110.1016/j.ijpharm.2007.10.021 ↗
32. Lee BK, Yun Y, Park K (2016) PLA micro-and nano-particles. Adv Drug Deliv Rev 107:176–19110.1016/j.addr.2016.05.020 ↗
33. Li F, Dou J, Wei L, Li S, Liu J (2016) The selective estrogen receptor modulators in breast cancer prevention. Cancer Chemother Pharmacol 77(5):895–90310.1007/s00280-016-2959-0 ↗
34. Li W, Shi X, Xu Y, Wan J, Wei S, Zhu R (2017) Tamoxifen promotes apoptosis and inhibits invasion in estrogen-positive breast cancer MCF-7 cells. Mol Med Rep 16(1):478–48410.3892/mmr.2017.6603 ↗
35. Liechty WB, Kryscio DR, Slaughter BV, Peppas NA (2010) Polymers for drug delivery systems. Annu Rev Chem Biomol Eng 1:149–17310.1146/annurev-chembioeng-073009-100847 ↗
36. Liu CY, Hung MH, Wang DS, Chu PY, Su JC, Teng TH, Huang CT, Chao TT, Wang CY, Shiau CW, Tseng LM (2014) Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A–dependent phospho-Akt inactivation in estrogen receptor–negative human breast cancer cells. Breast Cancer Res 16(5):43110.1186/s13058-014-0431-9 ↗
37. Liu S, Huang Z, Li F, Yan T, Fu S, Tian R, Hou C, Luo Q, Xu J, Liu J (2019) Supramolecular polymer nanocapsules by enzymatic covalent condensation: biocompatible and biodegradable drug-delivery systems for chemo-photothermal anticancer therapy. Polym Chem 10(26):3566–357010.1039/C9PY00523D ↗
38. Love RR (1989) Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. J Clin Oncol 7(6):803–81510.1200/JCO.1989.7.6.803 ↗
39. Lu B, Lv X, Le Y (2019) Chitosan-modified PLGA nanoparticles for control-released drug delivery. Polymers 11(2):30410.3390/polym11020304 ↗
40. Makadia HK, Siegel SJ (2011) Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 3(3):1377–139710.3390/polym3031377 ↗
41. Mandal B, Bhattacharjee H, Mittal N, Sah H, Balabathula P, Thoma LA, Wood GC (2013) Core–shell-type lipid–polymer hybrid nanoparticles as a drug delivery platform. Nanomedicine: NBM 9(4):474–49110.1016/j.nano.2012.11.010 ↗
42. Mandlekar S, Kong AN (2001) Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6(6):469–47710.1023/A:1012437607881 ↗
43. Massoumi B, Abbasian M, Jahanban Esfahlan R, Motamedi S, Samadian H, Rezaei A, Jaymand M (2020) PEGylated hollow pH responsive polymeric nanocapsules for controlled drug delivery. Polym Int 69(5):519–52710.1002/pi.5987 ↗
44. Meenach SA, Vogt FG, Anderson KW, Hilt JZ, McGarry RC, Mansour HM (2013) Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly (ethylene glycol)(DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. Int J Nanomedicine 8:275–293
45. Mishra P, Barik A, Parhi P, Dey RK (2016) Poly (ethylene glycol)-poly (lactic acid) polymeric micelles as novel drug delivery system in cancer therapy: an overview. Trends Biomater Artif Organs 30(2)
46. Moldeus P, Hogberg J, Orrhenius S, Fleischer S, Packer L (1978) Isolation and use of liver cells. Methods Enzymol 52:60–7110.1016/S0076-6879(78)52006-5 ↗
47. Molineux G (2002) Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat Rev 28:13–1610.1016/S0305-7372(02)80004-4 ↗
48. Mora-Huertas CE, Fessi H, Elaissari A (2010) Polymer-based nanocapsules for drug delivery. Int J Pharm 385(1–2):113–14210.1016/j.ijpharm.2009.10.018 ↗
49. Mora-Huertas CE, Garrigues O, Fessi H, Elaissari A (2012) Nanocapsules prepared via nanoprecipitation and emulsification–diffusion methods: comparative study. Eur J Pharm Biopharm 80(1):235–23910.1016/j.ejpb.2011.09.013 ↗
50. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1–2):55–6310.1016/0022-1759(83)90303-4 ↗
51. Nam KC, Han YS, Lee JM, Kim SC, Cho G, Park BJ (2020) Photo-functionalized magnetic nanoparticles as a nanocarrier of photodynamic anticancer agent for biomedical theragnostics. Cancers 12:57110.3390/cancers12030571 ↗
52. Nan Y (2019) Lung carcinoma therapy using epidermal growth factor receptor-targeted lipid polymeric nanoparticles co-loaded with cisplatin and doxorubicin. Oncol Rep 42(5):2087–2096
53. Nankali E, Shaabanzadeh M, Torbati MB (2020) Fluorescent tamoxifen-encapsulated nanocapsules functionalized with folic acid for enhanced drug delivery toward breast cancer cell line MCF-7 and cancer cell imaging. N-S arch Pharmacol 1-910.1007/s00210-020-01825-1 ↗
54. Negi JS (2019) Nanolipid materials for drug delivery systems: a comprehensive review. Elsevier Inc Chapter 610.1016/B978-0-12-814031-4.00006-4 ↗
55. Nguyen A, Marsaud V, Bouclier C, Top S, Vessieres A, Pigeon P, Gref R, Legrand P, Jaouen G, Renoir JM (2008) Nanoparticles loaded with ferrocenyl tamoxifen derivatives for breast cancer treatment. Int J Pharm 347(1–2):128–13510.1016/j.ijpharm.2007.06.033 ↗
56. Nicolas S, Bolzinger MA, Jordheim LP, Chevalier Y, Fessi H, Almouazen E (2018) Polymeric nanocapsules as drug carriers for sustained anticancer activity of calcitriol in breast cancer cells. Int J Pharm 550(1–2):170–17910.1016/j.ijpharm.2018.08.022 ↗
57. Nie ZY, Zhang MZ, Zheng DH, Zhang MX, Jia HQ, Zhang XD, Yue GC, Li XM, Liu P, Zhang YF, Liang K (2017) Enhanced antitumoral activity of quercetin against lung cancer cells using biodegradable poly (lactic acid)-based polymeric nanoparticles. J Biomater Tissue Eng 7(4):269–27410.1166/jbt.2017.1568 ↗
58. Ohsawa T, Miura H, Harada K (1985) Evaluation of a new liposome preparation technique, the freeze-thawing method, using L-asparaginase as a model drug. Chem Pharm Bull 33(7):2916–292310.1248/cpb.33.2916 ↗
59. Pandey R, Khuller GK (2004) Polymer based drug delivery systems for mycobacterial infections. Curr Drug Deliv 1(3):195–20110.2174/1567201043334669 ↗
60. Perumal O, Khandare J, Kolhe P, Kannan S, Lieh-Lai M, Kannan RM (2009) Effects of branching architecture and linker on the activity of hyperbranched polymer-drug conjugates. Bioconjug Chem 20(5):842–84610.1021/bc800526z ↗
61. Piacentini E (2016) Encapsulation efficiency. Encyclopedia of membranes Berlin Heidelberg: Springer:706–70710.1007/978-3-662-44324-8_1945 ↗
62. Piazzini V, Landucci E, Graverini G, Pellegrini-Giampietro DE, Bilia AR, Bergonzi MC (2018 Sep) Stealth and cationic nanoliposomes as drug delivery systems to increase andrographolide BBB permeability. Pharmaceutics. 10(3):12810.3390/pharmaceutics10030128 ↗
63. Pistelli M, Mora AD, Ballatore Z, Berardi R (2018) Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects. Curr Oncol 25(2):e168–e17510.3747/co.25.3735 ↗
64. Prabaharan M, Grailer JJ, Pilla S, Steeber DA, Gong S (2009) Folate-conjugated amphiphilic hyperbranched block copolymers based on Boltorn® H40, poly (l-lactide) and poly (ethylene glycol) for tumor-targeted drug delivery. Biomaterials 30(16):3009–301910.1016/j.biomaterials.2009.02.011 ↗
65. Prabha G, Raj V (2018) Synthesis and characterization of chitosan–polyvinylpyrrolidone–bovine serum albumin-coated magnetic iron oxide nanoparticles as potential carrier for delivery of tamoxifen. J Iran Chem Soc 15(4):871–88410.1007/s13738-017-1286-7 ↗
66. Rao S, Prestidge CA (2016) Polymer-lipid hybrid systems: merging the benefits of polymeric and lipid-based nanocarriers to improve oral drug delivery. Expert Opin Drug Deliv 13(5):691–70710.1517/17425247.2016.1151872 ↗
67. Remaut K, Lucas B, Raemdonck K, Braeckmans K, Demeester J, De Smedt SC (2007) Protection of oligonucleotides against enzymatic degradation by pegylated and nonpegylated branched polyethyleneimine. Biomacromolecules 8(4):1333–134010.1021/bm0611578 ↗
68. Rouhimoghadam M, Safarian S, Carroll JS, Sheibani N, Bidkhori G (2018) Tamoxifen-induced apoptosis of MCF-7 cells via GPR30/PI3K/MAPKs interactions: verification by ODE modeling and RNA sequencing. Front Physiol 9:90710.3389/fphys.2018.00907 ↗
69. Sengel-Turk CT, Gumustas M, Uslu B, Ozkan SA (2018) A novel approach for drug targeting: core-shell type lipid-polymer hybrid nanocarriers. In Design of Nanostructures for Theranostics Applications William Andrew Publishing:69–10710.1016/B978-0-12-813669-0.00003-8 ↗
70. Sharma N, Bhandari S, Deshmukh R, Yadav AK, Mishra N (2017) Development and characterization of embelin-loaded nanolipid carriers for brain targeting. Artif Cells Nanomed Biotechnol 45(3):409–41310.3109/21691401.2016.1160407 ↗
71. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM (2016) PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 99:28–5110.1016/j.addr.2015.09.012 ↗
72. Sur S, Rathore A, Dave V, Reddy KR, Chouhan RS, Sadhu V (2019) Recent developments in functionalized polymer nanoparticles for efficient drug delivery system. Nano-Struc Nano-Objec 20:10039710.1016/j.nanoso.2019.100397 ↗
73. Venditti I (2017) Morphologies and functionalities of polymeric nanocarriers as chemical tools for drug delivery: a review. J King Saud Univ Sci 31(3):398–41110.1016/j.jksus.2017.10.004 ↗
74. Vijayakumar MR, Muthu MS, Singh S (2013) Copolymers of poly (lactic acid) and D-α-tocopheryl polyethylene glycol 1000 succinate-based nanomedicines: versatile multifunctional platforms for cancer diagnosis and therapy. Expert Opin Drug Deliv 10(4):529–54310.1517/17425247.2013.758632 ↗
75. Wang S, Luo Y, Zhou J, Wang M, Wang Y (2018) PLA-PEG-FA NPs for drug delivery system: evaluation of carrier micro-structure, degradation and size-cell proliferation relationship. Mater Sci Eng C 91:297–30210.1016/j.msec.2018.05.049 ↗
76. Weng J, Huang Z, Pu X, Chen X, Yin G, Tian Y, Song Y (2020) Preparation of polyethylene glycol-polyacrylic acid block copolymer micelles with pH/hypoxic dual-responsive for tumor chemoradiotherapy. Colloids Surf B: Biointerfaces 11094310.1016/j.colsurfb.2020.110943 ↗
77. Yang C, Yu DG, Pan D, Liu XK, Wang X, Bligh SA, Williams GR (2016) Electrospun pH-sensitive core–shell polymer nanocomposites fabricated using a tri-axial process. Acta Biomater 35:77–8610.1016/j.actbio.2016.02.029 ↗
78. Yang WJ, Zhao T, Zhou P, Chen S, Gao Y, Liang L, Wang X, Wang L (2017) “Click” functionalization of dual stimuli-responsive polymer nanocapsules for drug delivery systems. Polym Chem 8(20):3056–306510.1039/C7PY00161D ↗
79. Yuan Y, Wu J, Li B, Niu J, Tan H, Qiu S (2018) Regulation of signaling pathways involved in the anti-proliferative and apoptosis-inducing effects of M22 against non-small cell lung adenocarcinoma A549 cells. Sci Rep 8(1):992–100110.1038/s41598-018-19368-0 ↗
80. Zhang H, Niu Q, Wang N, Nie J, Ma G (2015) Thermo-sensitive drug controlled release PLA core/PNIPAM shell fibers fabricated using a combination of electrospinning and UV photo-polymerization. Eur Polym J 71:440–45010.1016/j.eurpolymj.2015.08.023 ↗